Syngene launches platform for rapid, enhanced protein production

Sinequa Augments Companies with Release of New Generative AI Assistants

Sinequa announces new AI Assistants; Combining Sinequa’s Search with GenAI provides the ultimate AI Assistant and virtual coworker

The varvis® Software: The First Genomics End-to-End Software Certified as IVDR Class C Device

We are pleased to announce that Limbus Medical Technologies GmbH, a medical device manufacturer and software development company based in Rostock, Germany, has reached a significant milestone in the field of genetic diagnostics. The varvis® software is now the first complete genomics software solution certified as a Class C device under the In-Vitro Diagnostic Regulation (IVDR) EU 2017/746.

Qlucore starts project after receiving prestigious EU grant to advance personalized cancer treatment

Qlucore to receive a prestigious EIC Accelerator grant of 2,5 million Euros to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer.

AES Clean Technology Announces Appointment of New CEO

4D Path Announces New Data Highlighting Efficacy of the Q-plasia OncoReader (QPOR) Platform

We wanted to reach out today with some exciting, breaking news. 4D Path, a company dedicated to personalizing cancer care through their advanced approach to predicting tumor response announced this morning new clinical data regarding the efficacy of their patented Q-Plasia OncoReader (QPOR) platform, highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. "This is an exciting moment for oncology and pathology," said Stuart J. Schnitt, M.D., Chief of Breast Oncologic Pathology for the Dana-Farber Brigham Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Program. "The 4D Path QPOR Platform can potentially help inform researchers and clinicians about which patients are more or less likely to respond to neoadjuvant chemotherapy, paving the path for more precise and personalized treatments for patients." For the first time ever, we can unveil the dynamics of the tumor microenvironment, allowing biopharma and clinicians to get more targeted and precise in the development of therapies and treatment plans. Not only that, but the profound effects this will have on clinical trials and patient stratification, the benefits to pathologists and clinicians on the front lines with patients, and to patients – not only getting more targeted treatments but also helping the people who would have not responded, more effectively get to a treatment plan that might work. This is a monumental step forward in oncology. We would love to connect you with Satabhisa Mukhopadhyay, PHD, Chief Scientific Officer and Co-Founder of 4D Path, to provide more commentary regarding the importance of this moment and how their innovative, human approach (no AI, no machine learning) is allowing us to be more effective and specific when developing and implementing treatments. We would also be happy to discuss submitting an article authored by Satabhisa discussing these topics, and connect you with industry experts like Dr. Schnitt as well. We have placed below the press release for your reference. Please let us know if you have any questions. We are always available. Look forward to hearing from you.

Innovation and automation are driving forces behind next generation cell therapy manufacturing platform from Cytiva

PathAI Expands Portfolio of AI-Powered Products, Announcing PathExplore™ IOP and IHC Explore™ Ahead of ASCO 2024

PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™ to empower cancer drug developers and clinical researchers with AI-powered insights. The product pairing provides unprecedented single-cell and spatial resolution of the tumor microenvironment from routine pathology samples to facilitate biomarker discovery and deeper understanding of treatment response for the next generation of cancer therapeutics. The expansion of the Explore™ portfolio comes at a time when AI-pathology is experiencing accelerated large-scale adoption across the diagnostic and biopharma industries.

ZeOmega Names Tabatha Fuchs Chief Marketing and Communications Officer

Sakura Finetek Europe B.V. advances its laboratory automation with the Tissue-Tek xPrint® LP Laser Cassette Printer

Sakura Finetek Europe announces the launch of its newest advancement in tissue sample identification bringing laboratory workflows to the next level.

ResultsCX Achieves Coveted Great Place to Work® Certification™ Across Five Countries

Indica Labs Announces AI-Powered HALO® Software Release for Digital Pathology Research in Life Sciences

Indica Labs announced today the release of the transformative new version of its industry leading life sciences software.

SPT Labtech’s firefly® liquid handler chosen by Colossal Biosciences to accelerate NGS capabilities in fight against species extinction and biodiversity loss

Creative Enzymes Introduces Leaf-branch Compost Poly (ethylene terephthalate) Hydrolase for Sustainable PET Degradation

Study Demonstrates MyPhenome Hungry Gut Test Identifies Responders to Semaglutide

New independent study’s findings presented during Presidential Plenary session at Digestive Disease Week 2024.

Integrated DNA Technologies Invests in New U.S. Synthetic Biology Manufacturing Facility

Creative Enzymes Introduces Recombinant Porcine Citrate Synthase with Enhanced C-His Tag for Accelerated Metabolic Research

SPT Labtech and Watchmaker Genomics Partner to Simplify and Streamline NGS Library Preparation

PathAI and Aster Insights Partner to Deliver Combined AI-Derived Structured Pathology and Multimodal Real-World Data Solutions

PathAI, a global leader in AI-powered pathology, and Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a multi-year strategic partnership to develop curated multimodal datasets that pair PathAI’s PathExplore1 artificial intelligence (AI) tumor microenvironment (TME) quantification panel with Aster Insights’ Avatar clinical, molecular, and digital pathology imaging data. By combining their respective best-in-class platforms, PathAI and Aster Insights will be able to expedite the development of novel insights to accelerate the discovery and development of new treatments for patients with cancer.

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025.